273 related articles for article (PubMed ID: 30837596)
1. The genetic vulnerability to cisplatin ototoxicity: a systematic review.
Tserga E; Nandwani T; Edvall NK; Bulla J; Patel P; Canlon B; Cederroth CR; Baguley DM
Sci Rep; 2019 Mar; 9(1):3455. PubMed ID: 30837596
[TBL] [Abstract][Full Text] [Related]
2. Further Investigation of the Role of
Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD
Clin Cancer Res; 2018 Apr; 24(8):1866-1871. PubMed ID: 29358504
[No Abstract] [Full Text] [Related]
3. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Meta-Analysis of the Influence of Genetic Variation on Ototoxicity in Platinum-Based Chemotherapy.
Hong DZ; Ong TCC; Timbadia DP; Tan HTA; Kwa ED; Chong WQ; Goh BC; Loh WS; Loh KS; Tan EC; Tay JK
Otolaryngol Head Neck Surg; 2023 Jun; 168(6):1324-1337. PubMed ID: 36802061
[TBL] [Abstract][Full Text] [Related]
5. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
[TBL] [Abstract][Full Text] [Related]
6. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
7. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
Dillard LK; Lopez-Perez L; Martinez RX; Fullerton AM; Chadha S; McMahon CM
Cancer Epidemiol; 2022 Aug; 79():102203. PubMed ID: 35724557
[TBL] [Abstract][Full Text] [Related]
8. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
10. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
Vos HI; Guchelaar HJ; Gelderblom H; de Bont ES; Kremer LC; Naber AM; Hakobjan MH; van der Graaf WT; Coenen MJ; te Loo DM
Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270
[TBL] [Abstract][Full Text] [Related]
11. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
Xu H; Robinson GW; Huang J; Lim JY; Zhang H; Bass JK; Broniscer A; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Fisher M; Cohn R; Yamashita T; Teitz T; Zuo J; Onar-Thomas A; Gajjar A; Stewart CF; Yang JJ
Nat Genet; 2015 Mar; 47(3):263-6. PubMed ID: 25665007
[TBL] [Abstract][Full Text] [Related]
12. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
Brown AL; Lupo PJ; Okcu MF; Lau CC; Rednam S; Scheurer ME
Cancer Med; 2015 Nov; 4(11):1679-86. PubMed ID: 26400460
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.
Clemens E; Broer L; Langer T; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Byrne J; Broeder EVD; Crocco M; Grabow D; Kaatsch P; Kaiser M; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Kuehni CE; van der Pal H; Parfitt R; Deuster D; Matulat P; Spix C; Tillmanns A; Tissing WJE; Maier L; Am Zehnhoff-Dinnesen A; Zolk O; van den Heuvel-Eibrink MM;
Pharmacogenomics J; 2020 Apr; 20(2):294-305. PubMed ID: 31666714
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
El Charif O; Mapes B; Trendowski MR; Wheeler HE; Wing C; Dinh PC; Frisina RD; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Gamazon ER; Cox NJ; Huddart R; Ardeshir-Rouhani-Fard S; Monahan P; Fossa SD; Einhorn LH; Travis LB; Dolan ME
Clin Cancer Res; 2019 Jul; 25(13):4104-4116. PubMed ID: 30952644
[TBL] [Abstract][Full Text] [Related]
15. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
16. Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review.
Pearson SE; Taylor J; Patel P; Baguley DM
Int J Audiol; 2019 Nov; 58(11):685-695. PubMed ID: 31545660
[No Abstract] [Full Text] [Related]
17. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
18. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.
Riedemann L; Lanvers C; Deuster D; Peters U; Boos J; Jürgens H; am Zehnhoff-Dinnesen A
Pharmacogenomics J; 2008 Feb; 8(1):23-8. PubMed ID: 17457342
[TBL] [Abstract][Full Text] [Related]
19. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
[TBL] [Abstract][Full Text] [Related]
20. Ototoxicity Review: A Growing Number of Non-Platinum-Based Chemo- and Immunotherapies.
Naples JG; Rice-Narusch W; Watson NW; Ghulam-Smith M; Holmes S; Li D; Jalisi S
Otolaryngol Head Neck Surg; 2023 Apr; 168(4):658-668. PubMed ID: 35439087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
